The findings showed that disease progression not only worsens patient outcomes but also significantly increases overall healthcare costs. Late-stage disease and post-recurrence cystectomy were ...

Strengthen your security stack with Microsoft Defender for Endpoint for advanced threat protection, detection, and real-time defense.

With its framing as an all-American AI-RAN stack, ODC’s solution builds on Nvidia’s 6G AI-Wireless Intelligent Network ...

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society ...

Background Immunogenicity to SARS-CoV-2 vaccination in patients with SLE varies by vaccine type and immune-modulating therapy. However, data in Southeast Asian populations, especially among Thai ...

Emotional distress among adolescents in most participating countries was higher in 2022 than in 2018, with disproportionate ...

Whether infection of cells by individual virions occurs randomly or if there is some form (s) of competition or cooperativity between individual virions remains largely unknown for most virus-cell ...

Immunotherapy—could that be an option for me, doctor?” is a question frequently asked by patients with colorectal cancer. The ...

Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms natural killer (NK) cells to possess characteristics ...

Marks and Spencer is selling two slices of bread, specifically its Spanish Pan de Cristal product, for up to £4.50. Money reporter Jess Sharp brings you this and the rest of today's consumer and ...

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...

OPSWAT’s Jan Miller explains how the threat landscape is changing, why legacy defences are failing and what businesses must ...